Eli Lilly & Co. - LLY STOCK NEWS

Eli Lilly and Company (NYSE: LLY) announced its 2021 financial guidance, projecting revenue growth between $26.5 billion and $28.0 billion, with significant contributions from COVID-19 therapies. The company expects earnings per share (EPS) in the range of $7.25 to $7.90 on a reported basis. Lilly anticipates operating margins of approximately 30% and significant investments in R&D, including $6.5 billion to $6.7 billion for 2021. The updated guidance also reflects a 15% increase in dividends. Strong cash flow is projected to support shareholder returns and pipeline expansion.

Eli Lilly and Company (NYSE: LLY) has announced a 15% increase in its quarterly dividend, raising it to $0.85 per share for Q1 2021. This adjustment elevates the annual indicated rate to $3.40 per share. Shareholders of record on February 12, 2021, will receive the dividend on March 10, 2021.

Eli Lilly and Company (NYSE: LLY) announced the opening of patient enrollment for the New IDEAS Study, aimed at investigating the impact of amyloid PET scans on Alzheimer's disease patient management. This study will enroll 7,000 participants, focusing on diversity, with over 50% identifying as Black/African American or Hispanic/Latino. The initiative builds on the original IDEAS Study, which enrolled 18,000 participants. The New IDEAS aims to enhance understanding of amyloid imaging's role in patient care while addressing gaps in clinical trial diversity.

Eli Lilly and Incyte announced publication of peer-reviewed results from the Adaptive COVID-19 Treatment Trial (ACTT-2) in The New England Journal of Medicine. The Phase 3 study demonstrated that baricitinib, combined with remdesivir, shortened recovery times and lowered the risk of progression to ventilation or death in hospitalized COVID-19 patients. This supports the emergency use authorization (EUA) granted by the FDA on Nov. 19. Though not FDA-approved for COVID-19, baricitinib is authorized for use in hospitalized patients requiring supplemental oxygen.

Eli Lilly announced favorable results from the Phase 3 monarchE trial for Verzenio (abemaciclib), showing a 28.7% reduction in breast cancer recurrence risk in patients with hormone receptor-positive, HER2-negative early breast cancer when combined with standard adjuvant endocrine therapy.

The results, presented at the 2020 Virtual San Antonio Breast Cancer Symposium, indicated an improvement in invasive disease-free survival at 92.3% versus 89.3% in control. The data involved over 1,400 patients and showed consistent benefits across subgroups. Lilly plans to submit these findings to regulatory authorities by year-end 2020.

Eli Lilly's tirzepatide shows promising results for type 2 diabetes treatment, achieving an A1C reduction of 2.07% and body weight reduction of 9.5 kg in a 40-week trial. More than 51% of participants on the highest dose reached A1C levels below 5.7%, typically seen in non-diabetics. The safety profile is comparable to existing treatments, with gastrointestinal issues being the most common side effects. Tirzepatide is a novel dual GIP/GLP-1 receptor agonist, marking a milestone in diabetes care.

Eli Lilly and Company (NYSE: LLY) has announced it will provide its financial guidance for 2021 on December 15, 2020. The company will host a conference call at 8:30 a.m. Eastern time to elaborate on this guidance, which investors and the media can access via a live webcast on the company's website. Additionally, a replay will be available after the call. Lilly continues to focus on discovering and delivering life-changing medicines, reinforcing its commitment to high-quality healthcare.

Loxo Oncology at Lilly announced promising clinical data for LOXO-305, a selective BTK inhibitor, at the ASH Annual Meeting. The global Phase 1/2 BRUIN trial for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) showed a 63% overall response rate among evaluated patients. LOXO-305 demonstrated consistent efficacy regardless of prior therapies, with ongoing safety data indicating manageable adverse effects. With 88% of CLL/SLL patients remaining on LOXO-305, the company is set to initiate Phase 3 trials in 2021, potentially expanding treatment options for patients resistant to conventional therapies.

On December 5, 2020, Loxo Oncology at Lilly presented promising results from the LOXO-305 Phase 1/2 BRUIN trial for mantle cell lymphoma (MCL) and other B-cell malignancies at the ASH Annual Meeting. LOXO-305, a non-covalent BTK inhibitor, showed a 52% overall response rate (ORR) among 56 efficacy-evaluable MCL patients, including 14 complete responses. The company plans to initiate a Phase 3 trial in early 2021 to compare LOXO-305 to existing BTK inhibitors. Safety data indicates manageable side effects, positioning LOXO-305 as a potential new treatment option for patients with limited alternatives.